Friday - INSIGHT 2023

Developing the Current Status of Psychedelics in Psychiatry

In Conversation with a Recipient of Psychedelic Therapy Integrated with a Contextual Behavioural Therapy Approach for Complex Trauma

Henry Whitfield, M.Sc. (CBT/REBT) MBACP

10:30 am

Break

Old Medicines, New Misunderstandings

‘Finding Gold in the Shadow’ – The Challenges of Psychedelic Therapy from a Psychotherapeutic Perspective

Rob Coffey, M.Sc./MIACP

Neural Emotion- and Self-Processing With Psychedelics

Prof. Dr. Dr. Uwe Herwig

12:30 pm

Break

Panel II: Building the Mental Health Treatments of the Future – Between Neurobiological Effects and Phenomenological Diversity

Track 1

Audience Interaction

several rooms

2.45 pm

Introduction to Blitz World Café

3:00 pm

Blitz World Café

4:30 pm

Break

Track 1

Treatment II

Auditorium

The State and Future of Psychedelic Therapist Training

Dr. Elizabeth Nielson

5:35pm

Psychedelic Group Therapy

Dr. med. Peter Gasser

Track 1

Poster Session and Poster Awards

Foyer

The “Why“ of Psychedelic Drug Use – A Systematic Review of the Literature Investigating Motives to Use Serotonergic Psychedelics

Lukas Basedow, M.Sc.

The Antidepressant Effect of Acute Transdermal Ketamine on Behavioral Despair in Wistar Rats

MDMA Assisted Psychotherapy in Posttraumatic Stress Disorder: A Narrative Review Highlighting 5‐HT Mediated Neuroplasticity

Soma Makai-Bölöni, M.Sc.

The Role of Ego‐Dissolution and Connectedness in Psychedelic Experience

Ada Kaluzna B.Sc.

ACT as a Theoretical Framework for the Integration of Psychedelic Experiences

Dr. Paul Soons

Psilocybin in the Treatment of Anorexia Nervosa: the English Transition of a French 1959 Case Study

Rayyan Zafar, BSc. MSc.

Vincent Verroust PhD

Physiological, Cognitive and Animic Correlates of Self‐Blinding Microdosing Protocol Using Psilocybe Cubensis Mushrooms

Frederico Cavanna, LPsy

The Microdose.Me Study: A Large Scale Investigation of Psychedelic Microdosing Practices and Practitioner Characteristics

Joseph Rootman, M.A.

MDMA induced intimate bond or “monogamous hypersexuality”? A naturalistic case report

Justyna Holka-Pokoska, MD PhD FECSM

Psychedelic Therapy as Reality Transformation

Mateo Sanchez Petrement, RMa

7:05 am

Break

8:15 pm

Art and Music Exploratorium I+II

Track 2

Basic Research I

Bernhard von Langenbeck Room

9:00 am

Registration

Neural and Subjective Effects of Inhaled DMT in Natural Settings

Federico Zamberlan

Effects of Serotonin Reuptake Inhibitor (SSRI) Pretreatment on the Subjective Response to Psilocybin in Healthy Subjects

Anna Becker, M.Sc.

10:30 am

Break

Psychedelics as a Treatment for Alcohol use Disorder: Insights from Preclinical Models

Marcus Meinhardt, Ph.D.

Characterizing Thalamocortical (Dys)connectivity in LSD‐, D‐Amphetamine‐, and MDMA‐Induced Altered States of Consciousness

Dr. Mihai Avram

LSD Induces Increased Transcriptional Entropy in Rats’ Prefrontal Cortex

Aurora Savino, M.Phil.

12:30 pm

Break

Panel II: Building the Mental Health Treatments of the Future – Between Neurobiological Effects and Phenomenological Diversity

Track 2

Audience Interaction

several rooms

3:00 pm

Blitz World Café

4:30 pm

Break

Track 2

Basic Resarch II

Bernhard von Langenbeck

What Octopuses and Psychedelics Teach us About the Social Brain

Gül Dölen, M.D., Ph.D.

Safety First: Psychedelic Adverse Effects and Drug‐Drug Interactions

5:35pm

Dr. Kelan Thomas

Track 2

Poster Session and Poster Awards

Foyer

Lasting Effects of a Single Psilocybin Dose on Resting‐State Functional Connectivity in Healthy Individuals

Drummond McCulloch, B.Sc.

Changes in Time‐Varying Brain Activity Induced by Lysergic Acid Diethylamide (LSD)

Iga Adamska

Ketamine and Psilocybin Reduce Alcohol Intake in Addicted Rats

Ivan Skorodumov, M.Sc.

Psychedelic Microdosing ‐ Could it be More Than Just Placebo? A Discussion on the Current State of Research and Future Empirical Investigations

Laura Kärtner, M.Sc.

DMT Continuous Infusion ‐ Extending the Experience

Development and Validation of an LC‐MS/MS Method for the Bioanalysis of Psilocybin’s Metabolites, Psilocin and 4‐Hydroxyindole‐3‐Acetic Acid, in Human Plasma

Karolina Kolaczynska, M.Sc.

Towards a Neural Circuit Basis for Hallucinations: Striatal Dopamine Mediates Hallucination‐Like Perception in Mice

Torben Ott, Ph.D.

Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research

Julia Bornemann

LSD Alters Hippocampal‐Cortical Interactions in Freely Moving Rats

Carli Domenico, B.S.

Chemistry and Structure‐Activity Relationships of 5‐HT2A Selective Agonists

Jitka Nykodemová, M.Sc.

The Current State of Ayahuasca Research in Animal Models: A Systematic Review

Dimitri Daldegan-Bueno, M.Sc.

7:05 pm

Break

8:15 pm

Art and Music Exploratorium I+II

Track 3

Public Health I

Albrecht Kossel room

9:00 am

Registration

Can Psychedelics Improve Diet, Exercise, Meditation, and Weight Control?

Pedro J. Teixeira, Ph.D.

Can Psychedelics be Used to Improve Public Health?

10:30 am

Break

The Importance of Diversity in Psychedelic Science: A Global Call to Academics

Belief Changes Following a Single Psychedelic Experience : Results of a Survey Study

Psychedelic Retreats in Latin America: How to Make Them Safe, Sustainable and Respectful Toward Indigenous Peoples

Ludovica Sacchi, M.A.

12:30 pm

Break

Panel III: Is There Only One Way to Approval? Challenges in Implementing Psychedelic Substances in the Medical Field

Rigorously Evaluating Claims About the Scope and History of Traditional Psychedelic Use

Track 3

Anthropology

Albrecht Kossel room

2:45pm

Dr. Manvir Singh

Psilocybin Induced Changes in the Dimension of the Experience and Brain Dynamics Predict Long Term Positive Effects on Mood in Healthy Volunteers

3:15pm

3:45 pm

Discussion

4:30 pm

Break

Track 3

History

Albrecht Kossel room

Somatics & Psychedelics: How to use Body Awareness to Heal Trauma and Integrate and Unfold Intense Experiences

Johan Planefeldt, B.A.

Somatics & Psychedelics: How to use Body Awareness to Heal Trauma and Integrate and Unfold Intense Experiences

Johan Planefeldt, B.A.

Track 3

Poster Session and Poster Awards

Foyer

Amanita Muscaria – the Missing Link in the Chain of Western Psychedelic Research

Baiba Baika, M.A.

Psychedelic-assisted psychotherapy – A paradigm evolution

Helena Aicher, M.Sc.

Microdosing Placebo: An Expectation‐Controlled Study of the Subjective and Objective Effects of Placebo Psychedelics

George Fejer, M.Sc.

Psilocybin-Induced Enhancement of Long-Term Potentiation in Healthy Psychedelic-Naïve Participants

Hannah Douglass, M.Sc.

The Hidden Tool. A Qualitative Exploration of the Impact of the Psychedelic Experience on the Professional Development of Mental Health Workers

Ioana Ivan, Mrd.

Can Psychedelic Research Cast a Light on REM Sleep Function?

Dr. med. Umberto Pannacci

Effects of Psilocybin-Assisted Psychotherapy on the Emotional and Reward Processing of Music

Rebecca Harding, BSc

Psychedelics Use Predicts More Positive Emotional Reactivity and Greater Self‐Awareness: The Mediating Role of Ego Dissolution and Mystical Experiences

Anastasia Ruban, M.Sc.

The Effects of Psychedelics on Fear Extinction Recall: Research From Animal Studies in a Translational Perspective

Anna Schibli, B.Sc.

Psychedelic-assisted psychotherapeutic approaches: A narrative theoretical review

Mauro Cavarra, M.Sc.

7:05 pm

Break

8:15 pm

Music and Art Exploratorium I+II

Track 4

Implementation I

Rudolf-Virchow Room

9:00 am

Registration

After MDMA Approval – Outlook on Plans and Expected Developments

Amy Emerson

An Open Science Approach to Drug Development

Charles Raison, M.D.

10:30 am

Break

Advocacy for Psychedelics in the EU

Viktor Chvatal

Treatment Resistant Depression (TRD): A Regulatory Perspective on Recent Therapeutic Developments

Dr. med. Marion Haberkamp

Rethinking Venture Capital for a Novel Approach to Health & Wellness

Ozan Polat

12:30 pm

Break

Panel III: Is There Only One Way to Approval? Challenges in Implementing Psychedelic Substances in the Medical Field

Predicting Short and Long Term Effects of Psilocybin Containing Truffles on Selected Psychological Variables

Track 4

Implementation II: Ethics

Room 4

2:45pm

Maria Amato, M.Sc.

3:15pm

Psychedelics as Virtue Ethics

Arne Harms, Dr. Phil.

3:45 pm

Discussion

4:30 pm

Break

Track 4

Implementation III: Diversity and Access

Room 4

Psychedelics at a Crossroads: We Need Constructive Not Extractive Capital 

David Bronner

Experience as Medicine: Psychedelic Therapy and the Significance of Music

5:35pm

Mendel Kaelen, Ph.D.

Track 4

Poster Session and Poster Awards

Foyer

Zooming in and out Psychedelic Integration Process: Ideographic Network Analysis to Find Individual and Group Effects in High Density Longitudinal Process Data

Henry Whitfield, M.Sc. (CBT/REBT) MBACP

Dissolution of What? The Self Lost in Self‐Transcendent Experiences

Lena Lindström, M.Sc.

Case Presentation of a Patient Having a Ketamine Augmented Psychotherapy at OVID Practice

Dr. med. Sebastian Gaus

Dosing of Psychedelics

Friederike Holze, Ph.D.

LSD, Madness and Healing: Mystical Experiences as Possible Link Between Psychosis Model and Therapy Model

Isabel Wießner, M.Sc.

NLP on LSD: How the Language of Psychedelic Music Could Help Inform Music‐Selection in Therapy

Lasse Damgaard, M.Sc.

Psychological mechanisms of the effects of psychedelics ‐ from engaging stories to convincing evidence

Comparative Effects of Psilocybin versus Escitalopram on Rumination and Thought Suppression in Major Depressive Disorder

Tommaso Barba, M.Sc.

A Patient Reflection on the OVID Ketamine Augmented Psychotherapy: The Journey of Travelling From one Place to Another in Five Weeks.

Anthena Blak

Psychedelic Intimacy: Qualitative Exploration of Psychedelic States in Romantic Relationships

Jonas Neubert, B.A.

Artificial Wisdom

Luan van Pletsen, M.Eng.